Ensysce Biosciences to Participate in the 37th Annual ROTH Conference
Ensysce Biosciences (NASDAQ:ENSC), a clinical-stage pharmaceutical company focused on developing innovative severe pain relief solutions while minimizing opioid abuse and overdose risks, has announced its participation in the 37th Annual ROTH Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ensysce Biosciences (NASDAQ:ENSC), a clinical-stage pharmaceutical company focused on developing innovative severe pain relief solutions while minimizing opioid abuse and overdose risks, has announced its participation in the 37th Annual ROTH Conference.
The conference will take place from March 16-18, 2025, at the Laguna Cliffs Marriott Resort in Dana Point, CA. The company's leadership team, including CEO Dr. Lynn Kirkpatrick, CFO Dave Humphrey, and CCO Geoff Birkett, will be available for one-on-one investor meetings throughout the event.
Additionally, management will participate in a fireside chat on Tuesday, March 18th at 11:30am PT. Investors interested in scheduling meetings can contact Investor Relations at ENSC@mzgroup.us or their ROTH representative.
Details
News Market Reaction – ENSC
The recorded move for ENSC in the trading session of this news was -5.62%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced its participation in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA.
Ensysce's Chief Executive Officer Dr. Lynn Kirkpatrick, Chief Financial Officer Dave Humphrey, and Chief Commercial Officer Geoff Birkett will be available to host one-on-one meetings with investors during the event. In addition, management will participate in a fireside chat on Tuesday, March 18th at 11:30am PT. Interested parties can access the fireside chat here.
To schedule a one-on-one meeting with Ensysce's management, please contact Investor Relations at ENSC@mzgroup.us or your ROTH representative.
About Ensysce Biosciences
Ensysce Biosciences is a clinical stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
SOURCE: Ensysce Biosciences Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.